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AbstrAct
Stem cell marker, Musashi-1 (MSI1) is over-expressed in many cancer types; 
however the molecular mechanisms involved in MSI1 over-expression are not 
well understood. We investigated the microRNA (miRNA) regulation of MSI1 and 
the implications this regulation plays in colorectal cancer. MicroRNA miR-137 was 
identified as a MSI1-targeting microRNA by immunoblotting and luciferase reporter 
assays. MSI1 protein was found to be highly expressed in 79% of primary rectal 
tumors (n=146), while miR-137 expression was decreased in 84% of the rectal 
tumor tissues (n=68) compared to paired normal mucosal samples. In addition to 
reduced MSI1 protein, exogenous expression of miR-137 inhibited cell growth, colony 
formation, and tumorsphere growth of colon cancer cells. Finally, in vivo studies 
demonstrated that induction of miR-137 can decrease growth of human colon cancer 
xenografts. Our results demonstrate that miR-137 acts as a tumor-suppressive miRNA 
in colorectal cancers and negatively regulates oncogenic MSI1.
INtrODUctION
Colorectal cancer (CRC) is the 3rd most common 
cause of cancer-related deaths for men and women in the 
United States [1]. Worldwide, an estimated 1.4 million 
people were diagnosed with CRC in 2012 [2]. Although, 
screening methodologies have reduced the incidence of 
patients presenting with late stage disease at diagnosis, 
treating advanced stage colorectal cancer continues 
to challenge physicians. We are entering a new era of 
cancer research which depends on understanding the 
clinicopathological indexes paired with understanding 
the molecular footprint of cancer for improved tailored 
therapy, recently termed “precision medicine” [3, 4]. 
Recent evidence suggests that cancer originates from 
stem cell-like cells, termed tumor initiating cells (TICs) 
[5, 6]. It is believed that these stem-cell like cells are 
responsible for cancer initiation and also mediate 
metastasis and chemoresistance [6]. By gaining insight 
into the mechanisms of these rogue stem cell-like cells, 
targeted therapies can be designed against TICs. 
Recently, a stem cell regulator, Musashi-1 (MSI1), 
was discovered to be highly expressed in colon primary 
tumors and metastatic lesions in the lymph nodes as 
compared to paired adjacent normal colon mucosal tissue 
[7]. Furthermore, this study identified MSI1 as a novel 
prognostic biomarker and therapeutic target for treating 
colon cancer [7]. Knocking down MSI1 in human colon 
cancer cell lines reduces growth, enhances apoptosis 
after radiation treatment [8] and reduces colon cancer 
proliferation, migration and invasion in vitro [7]. 
Normally expressed in stem cells, MSI1 is an RNA 
binding protein which can inhibit translation of target 
mRNAs, including that of adenomatous polyposis coli 
(APC), NUMB and cyclin-dependent kinase inhibitor/
p21WAF-1 (CDKN1A) [9-11]. MSI1 represses translation 
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by binding to the 3′ untranslated region (3′UTR) of 
target mRNA, therefore inhibiting formation of the 80S 
ribosome complex [12]. By down-regulating NUMB, 
APC and p21WAF-1, MSI1 positively regulates the Notch 
and Wnt signaling pathways and promotes cell cycle 
progression [9-11]. Though MSI1 has been identified as a 
therapeutic target, the molecular mechanisms responsible 
for overexpression of MSI1 in some colorectal cancers 
are not well understood. One possibility is a dysregulation 
of microRNAs (miRNAs) that negatively regulate MSI1 
mRNA.
miRNAs are short, 20-22 nucleotide, non-coding 
RNAs that regulate gene expression by binding to the 
3ʹUTR of target mRNA thereby preventing protein 
translation or inducing mRNA destabilization [13]. 
miRNAs are predicted to target approximately 60% of 
all mRNAs, therefore, providing substantial regulatory 
power over many cellular processes [14]. The average 
3ʹUTR length of miRNA target genes is approximately 
1600 nucleotides, while non-miRNA target genes average 
1000 nucleotides [15]. MSI1 mRNA contains a long 
3ʹUTR (~1800 nucleotides) consistent with possible post-
transcriptional regulation by miRNAs. Recently, miRNAs 
negatively regulating MSI1 mRNA were identified and 
found to be dysregulated in glioblastoma [16]. In that 
study, an initial list of putative MSI1 targeting miRNAs 
was identified using the miRNA prediction program, 
TargetScan. Only the candidate miRNAs that had 
previously been reported to have implications in central 
nervous system tumors were examined for the ability to 
inhibit MSI1. This study provides substantial precedent 
that miRNAs regulate MSI1. We hypothesized that MSI1-
regulating miRNAs are dysregulated in colorectal cancer, 
producing an over expression of MSI1. The objective of 
this project was to study the post-transcriptional regulation 
of MSI1 by miRNAs in colorectal cancer. 
In this study, we show that miR-137 directly 
regulates MSI1. An inverse correlation between miR-137 
and MSI1 is revealed in a panel of colon cancer cell lines. 
Additionally, we found that MSI1 protein expression is 
more abundant in rectal tumors compared to paired 
adjacent and distant normal mucosa. Alternatively, miR-
137 levels are significantly decreased in rectal tumors 
compared to paired adjacent and distant normal mucosa. In 
vitro studies demonstrated that miR-137 over-expression 
decreases MSI1 expression, reduces cell growth, colony 
formation and tumorsphere growth. The restoration 
of miR-137 expression in xenograft tumor models 
also reduced tumor growth in vivo. Our work reveals a 
novel mechanism for MSI1 dysregulation in CRC and 
demonstrates miR-137 as a tumor suppressor miRNA. 
rEsULts
Identification of MSI-targeting miRNAs
MSI1 mRNA and protein is over-expressed in 
a panel of colon cancer cell lines compared to normal 
colon epithelial cell line, CCD-841 (Figure 1A). An 
apparent uncoupling of the mRNA and protein levels of 
MSI1 is revealed in this panel of cell lines, suggesting 
post-transcriptional regulation of MSI1. The molecular 
mechanism for MSI1 over-expression in colorectal cancer 
is not well understood. One possibility is a dysregulation 
of miRNA regulation. We utilized three miRNA targeting 
prediction programs (miRanda, TargetScan, PicTar) 
to identify highly conserved putative miRNA binding 
sites in MSI1 3′UTR. Using a variety of computational 
algorithms based on seed sequence position, pairing and 
conservation, these programs predict miRNA sites within 
target genes 3′UTR [17-19]. Among the three prediction 
programs, five overlapping miRNAs contained conserved, 
potential binding sites within MSI1 3′UTR; miR-125b, 
miR-137, miR-144, miR-185, and miR-342-3p (Figure 
1B, Supplemental Table 1). 
In order to determine which miRNAs negatively 
regulate MSI1 in colon cancer cell lines, miRNA mimics 
and a negative control (NC) mimic were transfected into 
high MSI1 expressing cell lines; HCT-116 and DLD-
1. Exogenous expression of miR-137 reduced MSI1 
protein levels compared to NC mimic in both HCT-116 
and DLD-1 cell lines (Figure 1C). Interestingly, miR-
125b and miR-342-3p mimics increased the expression 
of MSI1 in HCT-116 and DLD-1 respectively, suggesting 
an alternative mechanism of MSI1 regulation. Although 
this observation is beyond the scope of our current study, 
future studies focused on the miR-125b and miR-342-3p 
regulation of MSI1 may be of interest. Additional colon 
cancer cell lines HT29 and HCT-116 β/W were used to 
validate our findings, both of which displayed reduced 
MSI1 protein expression in cells transfected with miR-137 
mimic (Figure 1D). 
Since MSI1 is overexpressed in the panel of colon 
cancer cell lines, we hypothesized that miR-137 is down-
regulated. We analyzed the expression of pre and mature-
miR-137 in the same panel of colon cancer cell lines. In all 
five colon cancer cell lines examined, miR-137 expression 
was significantly decreased compared to the normal colon 
epithelial cell line, CCD-841 (Figure 1E). Normal human 
lung fibroblast cell line, WI-38, has similar miR-137 
expression levels as the normal colon cell line, CCD-841. 
As expected, miR-137 and MSI1 expression are inversely 
correlated in cell lines (P = .04, Fisher Exact Test).
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Figure 1: miRNA regulation of MSI1. (A) Expression of MSI1 mRNA and protein analyzed in a panel of colon cancer cell lines using 
quantitative real-time PCR and Western blotting. mRNA normalized to GAPDH and set relative to expression in normal colon epithelial 
cell line, CCD-841. (b) Venn diagram displaying highly conserved miRNAs predicted to bind to MSI1 3′UTR using miRanda, TargetScan 
and PicTar prediction software. (c) MSI1 protein expression analyzed in HCT-116 and DLD-1 colon cancer cell lines transfected with 
a panel of miRNA mimics as compared to cells transfected with a NC miRNA mimic. (D) MSI1 protein expression analyzed in HT29 
and HCT-116 β/W colon cancer cells lines transfected with miR-137 mimic as compared to cells transfected with a NC miRNA mimic. 
(E) Precursor and mature miR-137 expression was analyzed in a panel of cell lines using qRT-PCR and Taqman PCR. Pre-miR-137 was 
normalized to GAPDH and mature miR-137 expression was normalized to RNU6b. Expression data was set relative to CCD-841. 
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miR-137 directly regulates MSI1
Since miR-137 significantly decreased MSI1 protein 
expression in both HCT-116 and DLD-1 compared to the 
other mimics; we focused this study on understanding the 
miR-137-mediated regulation of MSI1. miR-137 reduced 
MSI1 protein expression in a dose-dependent manner 
(Figure 2A). Furthermore, miR-137 decreased MSI1 
mRNA levels more than cells transfected with NC mimic 
(P < .0001) and similarly as cells transfected with MSI1 
siRNA (Figure 2B). Alternatively, inhibiting endogenous 
miR-137 in HEK-293FT and HCT-116 using antagomiRs 
increased MSI1 protein expression (Figure 2C and 2D). 
Luciferase reporter assays were conducted to 
determine whether miR-137 inhibits MSI1 via the MSI1 
3′UTR. HEK-293FT cells were co-transfected with MSI1 
3′UTR luciferase reporter construct and miR-137 or NC 
mimic. As expected, miR-137 inhibited the luciferase 
Figure 2: miR-137 negatively regulates MSI1. (A) MSI1 protein expression in HCT-116 cells transfected with increasing 
concentrations of miR-137 mimic as compared to cells transfected with NC mimic. (b) Top, MSI1 mRNA and protein expression analyzed 
in HCT-116 cells transfected with NC mimic, miR-137 mimic and positive control, MSI1-siRNA. mRNA expression analyzed using qRT-
PCR, normalized to GAPDH and set relative to NC transfected cells. Bottom, MSI1 protein analyzed using Western blotting with β-actin 
as loading control. (c) MSI1 protein expression in HEK-293FT cells transfected with miR-137 antagomiR (137-Inh.), negative control 
antagomiR (NC-Inh.), miR-137 mimic (miR-137), negative control mimic (NC), MSI1 siRNA (si-MSI1) and a negative control siRNA 
(si-NC). Intensity of MSI1 protein was normalized to β-actin and set relative to control. Change in MSI1 protein shown in red. (D) MSI1 
protein expression in HCT-116 transfected with NC-Inh, miR-137-Inh, NC-mimic and miR-137 mimic. (E) HCT-116 cells were transfected 
with wild-type (WT) or mutant (mut) pSGG-MSI1 3′UTR luciferase construct with miR-137 or NC mimic. Data are means ± SE; n = 3; 
*** P < 0.001. 
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expression of the MSI1 WT 3′UTR construct (P < .0001), 
which was de-repressed by mutating the miR-137 seed 
sequence within the MSI1 3′UTR (Figure 2E). Our results 
confirm that miR-137 negatively regulates MSI1 via the 
MSI1 3′UTR. 
miR-137 down-regulates Wnt and Notch signaling 
If miR-137 successfully knocks down MSI1 levels, 
we would expect an increase in MSI1 target genes, p21 
and mNumb. As expected, in miR-137-transfected HCT-
116 cells, mNumb and p21 protein expression is increased 
compared to cells transfected with NC mimic (Figure 3A). 
MSI1 promotes cell growth by positively regulating Notch 
and Wnt signaling [20], therefore, we measured the change 
in both signaling pathways after miR-137 restoration. As 
measured by a β-catenin reporter (TOP/FOP) assay, miR-
137 significantly reduced Wnt signaling in HCT-116 cells 
(P < .0001) (Figure 3B). We also measured Wnt and Notch 
signaling target genes, c-Myc and Hes-1, in miR-137- and 
NC-treated HCT-116 and DLD-1 cells. Both c-Myc and 
Hes-1 mRNA and protein expression were significantly 
reduced in miR-137-treated HCT-116 cells compared to 
cells treated with NC mimic (P = 0.0003 and P < .0001) 
(Figures 3C and 3D). Since the MSI1 target, APC is 
homozygous mutated in DLD-1 cell line and unable to 
interact with β-catenin, we expected to see a minimal 
change in Wnt signaling in this cell line. Notch signaling 
was reduced in DLD-1 cells, indicated by reduced Hes-1 
mRNA (P = 0.002) and protein expression (Figures 3C 
and 3D). c-Myc mRNA (P = 0.0325) was slightly reduced 
in miR-137 treated DLD-1 cells; however there was no 
change in c-Myc protein expression in DLD-1 cells when 
treated with miR-137 (Figures 3C and 3D). Our data 
suggests that miR-137 reduces Wnt and Notch signaling 
pathways, in part by negatively regulating MSI1. 
To study the effect of constitutively active miR-
137, Tet-inducible miR-137 HCT-116 stable cells were 
produced using a pTRIPZ lentiviral expression vector. 
These stable clones are capable of inducing transcription 
of miR-137 when treated with doxycycline (DOX) to a 
physiological relevant level as compared to the expression 
of mature miR-137 in colon epithelial cell line, CCD-841 
(Supplemental Figure S1). The addition of DOX results in 
decreased MSI1 expression and downstream Notch and 
Wnt signaling targets, Hes1 and c-Myc (Figure 3E). The 
decreased MSI1 expression is also observed at the protein 
level (Figure 3F). In summary, miR-137 restoration in 
colon cancer cell lines significantly reduced Wnt and 
Notch signaling; two important oncogenic signaling 
pathways regulated by MSI1 and involved in colorectal 
cancer progression.
miR-137 acts as a tumor suppressor miRNA in 
colon cancer
Based on our preliminary data, we hypothesized 
that miR-137 acts as a tumor suppressor miRNA by 
negatively regulating MSI1. To examine the effect of 
miR-137 restoration on colon cancer cells, in vitro cell 
growth and cell viability assays were utilized. miR-137 
mimic transfected HCT-116 cells grew significantly less 
than cells treated with NC mimic (P < .0001) (Figure 4A). 
To examine whether the miR-137-induced cell growth 
inhibition was via MSI1 down-regulation, a phenotype 
rescue experiment was performed. miR-137 mediated 
inhibition of cell growth was partially restored when 
HCT-116 cells were co-transfected with a MSI1 cDNA 
expression vector that lacks the 3′UTR as compared to 
cells co-transfected with an empty vector (Figure 4B). This 
data suggests that miR-137 tumor suppressive function is 
mediated in part by negatively regulating MSI1. We also 
show that cell viability was significantly reduced upon 
miR-137 restoration as measured by a MTT cell viability 
assay (P < .0001) (Figure 4C). 
Since MSI1 is a regulator of intestinal multipotent 
stem cells [21], we predicted that miR-137 reduces 
clonogenic cell growth in colon cancer. miR-137 
significantly reduced clonal expansion of HCT-116 
cells (P < .0001) and DLD-1 (P < .0001), as determined 
by a colony formation assay (Figure 4D). Similarly, 
tumorsphere growth was also significantly reduced by 
approximately 52% (P = .0006) upon miR-137 restoration 
in HCT-116 cells (Figure 4E). Tet-inducible miR-137 
HCT-116 cells were transfected with either a MSI1 cDNA 
expression plasmid or control vector, in the presence or 
absence of DOX. In non-transfected cells, colonies grew 
significantly less when miR-137 expression was induced 
using DOX (P = .0055) (Figure 4F). However, when cells 
were transfected with MSI1 cDNA that lacks the 3′UTR, 
the colony formation capability was nearly completely 
restored (P = .0719) (Figure 4F).
In summary, miR-137 inhibits clonogenic growth, 
supporting its predicted role as a tumor suppressor miRNA 
that reduces colon cancer stem cell properties, in part by 
directly down-regulating MSI1.
miR-137 reduces tumor growth in vivo
To study the effect of constitutively active miR-
137 expression on tumor progression, HCT-116-miR-137 
Tet-on stable clones were subcutaneously injected into 
flanking sides of athymic nude mice. Ten mice (mean 
weight = 18.68 g ± 0.563) were randomly separated into 
two groups. One group of mice received 10 mg/ml DOX 
in the drinking water immediately following injection, 
while the second group of mice did not receive DOX. 
The induction of miR-137 decreased tumor growth by 
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Figure 3: miR-137 negatively regulates Notch and Wnt signaling in colon cancer cell lines. (A) MSI1, mNumb and p21 
protein expression was analyzed in HCT-116 cells transfected with miR-137 and NC mimics. (b) HCT-116 cells were transfected with Top 
or Fop Flash constructs and miR-137 or NC miRNA mimic. Wnt signaling was stimulated with 20 mM LiCl for 16 h. Top Flash luciferase 
values were normalized to Fop Flash luciferase values. Data are means ± SE; n = 3; **P < 0.001. (c) mRNA expression of Hes-1 and c-Myc 
was analyzed in HCT-116 and DLD-1 cells transfected with miR-137 or NC mimic using qRT-PCR. Expression data was normalized to 
GAPDH and set relative to NC. Data are means ± SE; n = 3; *** P < 0.001, **P < 0.01, *P < 0.05. (D) Protein expression of c-Myc and 
Hes-1 in HCT-116 and DLD-1 cells transfected with NC mimic and miR-137 mimics. GAPDH is loading control. (E) Tet-on miR-137 HCT-
116 cells were treated with increasing doses of DOX. Expression of mature miR-137 was analyzed using Taqman qRT-PCR, normalized to 
RNU48 and set relative to cells treated without DOX. MSI1, Hes1 and c-Myc mRNA was analyzed using qRT-PCR, normalized to GAPDH 
and set relative to cells treated without DOX. Data are means ± SE; n =3. (F) Tet-on miR-137 and NC HCT-116 cells were treated with 
1 ug/ml DOX for 24, 48 and 72 hours. MSI1 protein was analyzed using Western blotting. β-actin used as loading control for Westerns. 
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Figure 4: miR-137 inhibits colon cancer growth and clonogenic growth by inhibiting MSI1. (A) Cell growth curve in HCT-
116 cells transfected with miR-137 and NC mimic. Cells were collected and counted every day for 4 days. Data are means ± SE; n = 3; *** 
P < 0.001. (b) Cell growth curve in HCT-116 cells co-transfected with miR-137/NC mimic and EV-GFP/MSI1-GFP expression vectors. 
Cells were collected and counted every day for 4 days. Data are means ± SE; n = 2; **P < 0.01, *** P < 0.001. (c) Cell viability was 
measured using a MTT colorimetric assay in HCT-116 cells transfected with miR-137 and NC mimic. (D) Colony formation assay in HCT-
116 and DLD-1 cells transfected with miR-137 and NC mimic. Image of representative colonies are shown in right panel. (E) Tumorsphere 
assay in HCT-116 cells transfected with miR-137 and NC mimic. Data are means ± SE; n = 3; *** P < 0.001. (F) Colony formation on 
Tet-on miR-137 cells transfected with MSI1-GFP or EV-GFP constructs. Cells were plated in media with and without 1 μg/ml DOX. Data 
are means ± SE; n = 2; *P < 0.05, **P<0.01 and ***P < 0.001. 
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Figure 5: miR-137 inhibits human colon cancer xenografts growth. (A) Tet-on miR-137 HCT-116 cells were injected into 
subcutaneously into mice. 10 mg/ml DOX was administered to the drinking water of one group of mice immediately following injections. 
Average tumor size was calculated at the end of the study and averaged for each group (on right). (b) Tet-on miR-137 and NC HCT-116 
cells were injected into mice. After tumors grew to be approximately 50 mm3 in size, both groups of mice were given 10 mg/ml DOX in 
their drinking water. Average tumor size was calculated at the end of the study and averaged for each group (on right). (c) MSI1 protein 
expression was analyzed in three tumor samples from Tet-on miR-137 and NC HCT-116 xenograft samples. β-actin was used as loading 
control. (D) Relative mature miR-137 expression and relative MSI1 protein expression in xenografts tumor samples. Data are means ± SE; 
n = 3; *P < 0.05, **P < 0.01 and ***P < 0.001. 
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approximately 75% (n = 8, P = .003, day 33) compared 
to the tumor growth in mice not fed DOX (n=10) (Figure 
5A). 
To control for DOX’s effect on tumor growth, a 
separate animal experiment was performed using HCT-
116 NC and miR-137 stable cells. Ten mice (mean weight 
= 22.1 g ± 0.458) were randomly separated into two 
groups. After cells were injected subcutaneously, both 
groups of mice were fed DOX in their drinking water once 
tumor volumes reached approximately 50 mm3. Similar 
to the previous animal study, the induction of miR-137 
significantly inhibited colon cancer xenograft tumor 
growth by 55% (n=10, P < .0001, day 22), as compared to 
mice inoculated with inducible NC mimic (n=10) (Figure 
Figure 6: Musashi-1 is over expressed and miR-137 is decreased in rectal cancer tissue samples. (A) Expression of MSI1 
in a variety of cancer types is correlated with survival using PrognoScan database. (b) Kaplan-Meier curve associated with the colorectal 
dataset GSE17537. High MSI1 correlates with poor overall survival. Analyzed using PrognoScan database, Log-rank test, P = 0.0151. (c) 
Representative images of MSI1 immunohistochemistry in distant normal rectal mucosal tissues (left panel) and rectal primary tumor tissue 
(right panel). Bar = 5 μm. Magnification: 40x. (D) MSI1 intensity scores were categorized into low expressing (TMA scores of 0+1+2) 
and high expressing (TMA scores of 3). The percentage of low and high MSI1 expression was calculated for each tissue type. (E) Mature 
miR-137 expression was analyzed in 68 pairs of normal and primary rectal tumor tissues using Taqman PCR. miR-137 was normalized to 
RNU6b and set relative to matching normal. *** P < 0.001. (F) The overall survival of 93 patients was analyzed comparing decreased and 
increased expression of miR-137 using Kaplan-Meier survival analysis. 
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5B). 
Tumors were excised at the end of the study to 
analyze the expression of miR-137 and MSI1. The protein 
expression of MSI1 was decreased in the miR-137-
treated tumors as compared to NC tumors (P = .0124) 
(Figure 5C and 5D). Additionally, miR-137 expression 
was significantly increased in the Tet-on miR-137 tumors 
compared to NC xenografts (P < .0001) (Figure 5D). In 
summary, induction of miR-137 significantly inhibited the 
human colon cancer xenograft tumor growth. Collectively 
the data supports our hypothesis that miR-137 acts as 
a tumor suppressor miRNA by down-regulating the 
oncogenic MSI1 that subsequently leads to tumor growth 
inhibition. 
Expression of MSI1 and miR-137 in patient tumor 
samples
In order to understand the clinical relevance of 
our study, we used PrognoScan [22], a database used 
to correlate gene expression with patient prognosis, to 
determine the correlation between MSI1 expression with 
overall survival in patients with a variety of cancer types. 
Patients with high MSI1 expression was significantly 
correlated with an increased hazards risk for poor overall 
survival in patients with bladder cancer (n = 165, P = 
0.0150), AML (n = 34, P = 0.0002), colorectal cancer (n = 
55, P = 0.0151) and ovarian cancer (n = 133, P = 0.0019) 
(Figures 6A). In the colorectal dataset (GSE17537), 
high MSI1 significantly correlates with increased hazard 
risk, analyzed using a Kaplan-Meier curve and Cox 
proportional hazards regression test (Figure 6B). 
We also examined the expression of MSI1 and 
miR-137 in available tissue samples from patients with 
rectal cancer. MSI1 protein expression was analyzed 
using immunohistochemistry in distant normal mucosa, 
adjacent normal mucosa, primary tumor and lymph node 
metastasis tissue samples collected from patients with 
rectal cancer (Figure 6C). The average score for MSI1 
intensity was significantly higher in tumor samples 
collected from primary tumor (P < .0001) and metastatic 
lesions (P < .0001) (Supplemental Table 3) as compared 
to distant normal and adjacent normal mucosal tissue 
samples. For analysis, samples were categorized into 
high MSI1 expressing with intensity scores greater than 
two, while scores equal to or less than two were defined 
as low MSI1 expressing. MSI1 was highly expressed in 
79% of primary tumor samples, and 53% of metastatic 
lesion samples. Inversely, MSI1 was highly expressed in 
1% of distant normal samples and 8% of adjacent normal 
samples (Figure 6D and Supplemental Table 4). 
The expression of miR-137 was measured in 68 
paired normal mucosal and primary tumor tissue samples 
using Taqman qRT-PCR. miR-137 was significantly 
decreased in 84% of primary tumor tissue samples 
when compared to the paired adjacent normal tissues 
(n = 68, P < .0001) (Figure 6E and Supplemental Table 
5). The expression of miR-137 did not statistically 
correlate with MSI1 expression in tissue samples (P 
= 0.54, Supplemental Table 6), although a clear trend 
is revealed in our patient data analysis and provides 
important precedence that analyzing more patients for 
the expression of MSI1 and miR-137 is needed in order 
to obtain statistical significance. Correlating miR-137 
expression with patient survival demonstrated that patients 
with decreased miR-137 had an increased hazard of death 
(HR = 0.61) as compared to patients with no change or 
increased expression of miR-137, although this did not 
reach statistical significance (P = .269) (Figure 6F). In 
conclusion, our results show that miR-137 expression 
is decreased in colon cancer cell lines and rectal cancer 
tissues, and supports our overall hypothesis that loss 
of miR-137 promotes the overexpression of MSI1 in 
colorectal cancer. 
DIscUssION
In the current study, we show that miR-137 can 
regulate MSI1 in colon cancer cell lines. We revealed an 
inverse correlation between miR-137 and MSI1 in a panel 
of colon cancer cell lines as compared to a normal colon 
epithelial cell line, and in primary rectal tumor tissues as 
compared to paired normal rectal mucosal tissue. miR-
137 restoration in colon cancer cell lines, reduces MSI1 
mRNA and protein levels, and inhibits cell growth, 
colony formation and tumorsphere growth. Furthermore, 
expressing miR-137 in HCT-116 significantly reduces 
xenografts tumor growth. In conclusion, our data suggest 
that miR-137 acts as a tumor suppressive miRNA and 
when down-regulated promotes tumorigenesis through the 
up regulation of MSI1. 
Multiple studies have found an overexpression of 
MSI1 in a broad range of cancer types, including breast, 
lung and colon cancer [7, 8, 23, 24]. We are the first to 
report an overexpression of MSI1 specifically in rectal 
cancer in a large patient cohort. Although colon and rectal 
cancer are often grouped together under the category 
of colorectal cancer, their treatment strategies differ 
significantly. For colon cancer, typically surgical resection 
combined with chemotherapy is the primary treatment 
strategy [25]. For rectal cancer, radiation therapy combined 
with surgical resection is commonly used [25]. Previous 
studies have found that MSI1 knockdown sensitizes colon 
cancer cells to radiation therapy [8]. Collectively, this 
suggests that future therapeutic strategies targeting MSI1 
may be relevant for both colon and rectal cancer patients 
and possibly in combination with conventional treatment 
strategies, such as radiation therapy. We hope to address 
these possibilities in future studies. 
One aim of our study was to understand why MSI1 
is overexpressed in colorectal cancer. As shown in the 
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small intestine and colon tissue of adult and developing 
mice, MSI1 is predominately expressed in the base of 
crypts and less so towards the top of the transit amplifying 
region of the crypt, before reaching the villus location.[21] 
Stem cell genes are often tightly regulated by miRNAs 
upon differentiation [26, 27]. We propose that a lack of 
miRNA regulation during proliferation and subsequent 
differentiation of colon stem cell progeny causes MSI1 
overexpression in colorectal cancer. The purpose of this 
study was to identify miRNAs capable of negatively 
regulating MSI1 in hopes of learning more about the 
potential cause of MSI1 overexpression in colorectal 
cancer. We successfully identified miR-137 as a negative 
regulator of MSI1 in colon cancer cells. Our findings are 
consistent with a previous study that discovered miR-137 
as a negative regulator of MSI1 in a glioblastoma cell 
model [16]. 
Taken together, the data suggests that in normal 
cells, MSI1 is negatively regulated by miR-137, possibly 
during differentiation, and this level of regulation has 
been dismantled in colorectal cancer cells, thus leading 
to the MSI1 overexpression. Previous studies have shown 
that miR-137 expression increases upon differentiation of 
neural stem cells [28, 29] and mouse embryonic stem cells 
[30]. In cancer, miR-137 has been shown to be decreased 
in glioblastoma [29, 31], melanoma [32], gastric cancer 
[33], and colorectal cancer [34-36]. 
According to our results, loss of miR-137 appears 
to be at the transcriptional level since both pre and mature 
forms of miR-137 were decreased in colon cancer cell 
lines. Our data is consistent with previous studies that 
discovered loss of miR-137 occurs early in the progression 
of colon cancer due to hypermethylation of the promoter 
region [34], which prevents binding of the transcription 
factor, high-mobility group AT-hook (HMGA)1 [36]. 
This observation strongly supports our results and overall 
hypothesis that in colon cancer, miR-137 expression is 
silenced during differentiation due to hyper-methylation, 
resulting in MSI1 over-expression. However this specific 
mechanism needs to be studied further. 
Overall, we describe an important tumor-
suppressive mechanism of miR-137 through the negative 
regulation of MSI1 and Notch/Wnt signaling, outlined in 
our working model (Figure 7). miR-137 is a promising 
Figure 7: Working model. RNA binding protein and stem cell regulator, MSI1, positively regulates the Wnt and Notch signaling 
pathways by binding to and inhibiting the translation of target mRNA; APC, p21WAF-1, and NUMB. In this study, we show that miR-137 acts 
as a tumor suppressive microRNA, in part by negatively regulating MSI1 and subsequently Wnt and Notch signaling pathways. 
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candidate for future miRNA-based molecular therapy for 
treating a variety of cancer types, including colorectal 
cancer. Our findings provide insight into the mechanism 
of dysregulation of colon cancer stem cells and eventually 
colorectal cancer initiation and progression. By 
understanding the molecular mechanisms of colorectal 
cancer biology, therapies may be developed to better 
combat this deadly disease.
MATERIALS AND METHODS
Patient samples and tissue microarray
Tissue microarray (TMA) slides were prepared 
from formalin-fixed paraffin embedded tissue blocks 
and contained tissue specimens from 146 primary rectal 
adenocarcinoma samples, 116 distant normal mucosa 
samples, 80 adjacent normal mucosa specimens, and 49 
lymph node metastases. Tissue samples were collected 
from patients enrolled in a randomized clinical trial 
testing preoperative radiation therapy in the Southeast 
region of Sweden [37]. Distant normal mucosa was taken 
from proximal or distal margin (4-35 cm from the primary 
tumor) of the resected rectum and adjacent normal mucosa 
was taken from the mucosa tissue adjacent to the primary 
tumor. Both normal sections were histologically free from 
tumor. Additional details regarding the patient cohort 
and tumor characteristics are presented in Supplemental 
Table 2. Each patient was provided detailed information 
about the study aims and protocol, and gave their 
written informed consent prior to enrollment. The study 
was approved by the Institutional Review Board of the 
Linköping University, Sweden.
PrognoScan analysis
The correlation between MSI1 expression and 
patient prognosis was evaluated using the PrognoScan 
database (http://www.abren.net/PrognoScan/) [22]. Using 
the minimum P-value approach, patients samples are 
grouped into high and low MSI1 expressing groups and 
correlated with survival using a Kaplan-Meier curve and 
log-rank test. Hazard risk is tested using a cox proportional 
hazards regression analysis. 
Immunohistochemistry of TMA
Immunohistochemistry was performed on TMA 
slides according to our previous publication [38]. Anti-
Musashi-1 rabbit monoclonal antibody was used at a 
dilution of 1:50 (EMD Millipore, Billerica, MA, United 
States). A negative control experiment was performed 
using tissue samples from primary rectal cancer, incubated 
with PBS rather than anti-Musashi-1 primary antibody 
and probed with secondary anti-rabbit antibody to detect 
background signal produced by the secondary antibody 
(data not shown). The specificity of the anti-MSI1 
antibody (Millipore, 04-1041) was tested in HEK-293FT 
cells treated with a MSI1-siRNA and NC-siRNA using 
Western blotting (data not shown). Specific details of the 
reagents and material used for this study are outlined in 
Supplemental Table 7. 
Since MSI1 was homogeneously expressed in the 
epithelial cells among the tumor tissue sections, only 
MSI1 intensity was scored. Scoring was performed by 
two trained scientists independently without knowledge 
of clinicopathological information and reviewed by a 
pathologist. Each tissue sample had three replicate tissue 
cores included in the TMA. The highest TMA score for 
the three replicates was used as a representative score and 
the average intensity score between the two independent 
scorers was used as a final representative TMA score for 
each tissue sample. Scoring was based on MSI1 intensity: 
scores 0 displayed no visible MSI1 staining (negative), 
scores 1, 2 and 3 were weak, moderate and strong MSI1 
staining. 
Taqman microRNA analysis in patient tissue 
samples
MicroRNA was isolated from paraffin-embedded 
tissue sections from rectal cancer patients using 
RecoverAll™ Total Nucleic Acid Isolation Kit for 
FFPE (Life Technologies, Stockholm, Sweden). The 
microRNA quality was assessed by studying amplification 
efficiencies of microRNAs after serial dilutions of cDNA 
and measuring CT values of microRNAs using real 
time PCR. miR-137 expression was determined using 
Taqman microRNA assay and normalized to control small 
RNA, RNU6b. The expression of miR-137 in the tumor 
samples was normalized to RNU6b and set relative to the 
expression of miR-137 in normal mucosal samples. 
Cell culture and reagents 
The following cell lines were purchased from 
American Type Culture Collection (ATCC, Manassas, VA, 
United States); HCT-116, DLD-1, SW480, HT29, 293 FT, 
293 WT, CCD-841 CoN and passaged according to ATCC 
protocol. HCT-116 β/W cell line was a generous gift from 
Bert Vogelstein (The Johns Hopkins University School 
of Medicine) [39]. Cells were cultured in Dulbecco’s 
modified Eagle medium (Sigma-Aldrich, St. Louis, MO, 
United States), supplemented with 10% fetal bovine 
serum (GE Healthcare HyClone, Logan, Utah, United 
States), and 1% Penicillin-Streptomycin antibiotic (Life 
Technologies, Grand Island, NY, United States). 
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In vitro studies
miRNA mimics, siRNAs, NC mimics, NC siRNA, 
miR-137 antagomiR and antagomiR-NC were purchased 
from Dharmacon (GE Dharmacon, Lafayette, CO, United 
States). Transfections were carried out as previously 
described [40]. Briefly, cells plated in a 6-well plate 
were transfected with 100 pmol (50nM) miRNA mimics, 
siRNAs or antagomiRs using Lipofectamine 2000 
(Invitrogen, Life Technologies). For cell growth assays, 
HCT-116 cells were transfected with miR-137 mimic 
and negative control (NC) mimic and re-seeded 24 hours 
later in a 24-well plate. Cells were collected every day for 
4 days and living cells were counted using trypan blue 
staining and a hemocytometer as previously described 
[41]. For the cell growth rescue experiment, cells were 
co-transfected with miR-137 and NC mimics (50nM) 
and the MSI1-GFP/EV-GFP expressing constructs (1 µg) 
for 24 hours and re-seeded in a 24-well plate. Cells were 
collected and counted as described above every day, for 4 
days. Cell viability of cells was determined using a MTT 
colorimetric assay. Briefly, cells were transfected with 
miR-137 and NC mimics, 24 hours later cells were re-
seeded into a 96-well plate in triplicate. After 4-6 days 
(or until ~90% confluency of NC group), cell medium 
was replaced with WST-8 (Sigma) dye for 1-5 hours. 
The absorbance was quantified using a microplate reader 
(BioTek, Winooski, VT, United States) at 450 nm. The 
absorbance of miR-137-treated cells was set relative to 
cells treated with NC mimic. 
Western blot analysis
After 48-72 hours of transfection with mimics, 
antagomiRs, or siRNAs, cells were collected for Western 
blotting as previously described [42]. Antibodies used for 
our studies are detailed in Supplementary Table 7. 
Luciferase reporter assays
The pSGG-MSI1 3′UTR luciferase construct was 
a gift from Luiz O.F. Penalva and previously described 
[43]. Cells were transfected with 200 ng of pSGG-MSI1 
3′UTR luciferase construct and 20 nM miR-137 mimic or 
NC mimic using Lipofectamine 2000. Three nucleotides 
within the miR-137 seed sequence in the pSGG-MSI1-
3′UTR construct were mutated using the QuikChange 
Site-Directed Mutagenesis Kit (Agilent, Santa Clara, CA, 
United States). After 48 hours, cells were harvested and 
assayed using the Dual-Luciferase Reporter Assay System 
(Promega, Madison, WI, United States). Wnt signaling was 
measured using the TOP/FOP Flash reporter constructs 
(Millipore). Cells were transfected with 200 ng of TOP or 
FOP Flash constructs and 20 nM miR-137 mimic or NC 
mimic using Lipofectamine 2000. Transfected cells were 
stimulated with 20 mM LiCl for 16 hours prior to harvest 
at 48 hours post-transfection. A renilla luciferase construct 
was used as a normalizing control for all luciferase assays. 
Experiments were conducted in triplicate.
Quantitative real-time PCR
Quantitative real-time PCR was performed 
using gene specific primers (Supplemental Table 
8), SYBR® Select master mix (Applied Biosystems, 
Life Technologies) and normalized to GAPDH. The 
expression of mature miR-137 was quantified using 
microRNA TaqMan® Assays (Life Technologies) and 
normalized to housekeeping small RNAs, RNU6b or 
RNU48 (Supplemental Table 7). Expression of genes were 
normalized using the equation 2-ΔCt = 2-(Ct (housekeeping gene) – Ct 
(gene of interest)) [44].
Colony formation and tumorsphere assay
Colony formation assays were performed using 
HCT-116 cells transfected with 100 pmol mimics (miR-
137 and NC) in a 6-well plate for 24 hours and then 
re-seeded (300 cells/well) in a 6-well plate in triplicate 
according to our previous publication [40]. For the 
tumorsphere assay, HCT-116 cells were transfected as 
described above and re-seeded into 24-well ultra-low 
attachment plates in triplicate at 2000 cells per well 
according to our previous publication [45]. The number 
of colonies and tumorspheres grown in miR-137 treated 
cells was set relative to the number of tumorspheres 
grown in NC treated cells. A rescue experiment was 
performed using a colony formation assay and a pCMV6-
MSI1-GFP construct purchased from Origene (Rockville, 
MD, United States). A pCMV6-EV-GFP construct was 
produced by removing the MSI1 coding sequence from 
Sgf1/Xho1 sites and replacing it with a 24 base pair linker; 
5′-TCACAACCTCCTAGAAAGAGTAGA-3′. 
Production of Tet-on HCT-116 stable cell lines
The mature miR-137 or NC mimic sequence was 
cloned into the Tet-inducible pTRIPZ expression vector 
(Dharmacon) according to manufacturer’s instructions. 
Stable cell lines were generated by lentiviral transduction 
of HCT-116 cells and selected with 1.2 µg/ml puromycin 
for 1 week. Cells were treated with 0.25, 0.5 or 1 μg/ml of 




Animal experiments were done according to the 
Institutional Animal Care and Use Committee (IACUC) 
protocol approved by the University of Kansas Guidelines 
for Use and Care of Animals. HCT-116 stable clones with 
inducible miR-137 and NC miRNA were injected (0.5 
x 106) into sub-cutaneous regions 5-6 week old, female 
athymic nude mice (Hsd:Athymic Nude-Foxn1nu, Harlan). 
Mice were separated into control and experimental groups 
randomly (N=5/group) for each animal study. In the 
tumor progression experiment, after the tumors reached 
approximately 50 mm3 in size, mice were fed 1 mg/ml 
Doxycycline Hyclate (Sigma) in the drinking water to 
induce the expression of miR-137 or NC miRNA. In the 
tumor initiation study, DOX (1 mg/ml) was administered 
immediately after cell injections. Tumor growth was 
measured using calipers, 2-3 times per week. To avoid 
biased interpretations, scientists measuring tumor volume 
were unaware of treatment groups. Tumor volume 
was calculated using the following equation: (length x 
width2)/2. 
Statistical analysis
Chi-square test was used to examine the significance 
of the differences in MSI1 expression in distant or 
adjacent normal mucosa, primary cancer and lymph node 
metastasis, as well as the correlation of MSI1 expression 
and miR-137 expression with clinicopathological 
variables. miR-137 expression with overall survival was 
tested using Log-Rank and Cox proportional hazards 
regression analysis. Survival curves were computed 
according to Kaplan-Meier estimates. Two-way ANOVA 
test was utilized to study the significance of the cell 
growth curve and xenograft tumor growth studies. All tests 
were two sided and a P-value (P) of < .05 was considered 
statistically significant. Data represent average results 
from at least three independent experiments and shown 
as the mean ± SE. *P < .05; **P < .01; and ***P < .001. 
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